How big is Nurix Therapeutics, Inc.?

As of Jun 18, Nurix Therapeutics, Inc. has a market capitalization of 868.32 million, with net sales of 56.41 million and a net profit of -208.41 million over the last four quarters. The company reported shareholder's funds of 526.99 million and total assets of 675.43 million as of Nov 24.

Market Cap: As of Jun 18, Nurix Therapeutics, Inc. has a market capitalization of 868.32 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Nurix Therapeutics, Inc. reported net sales of 56.41 million and a net profit of -208.41 million.<BR><BR>Balance Sheet Snapshot: As of Nov 24, the company reported shareholder's funds of 526.99 million and total assets of 675.43 million.

What does Nurix Therapeutics, Inc. do?

Nurix Therapeutics, Inc. is a biopharmaceutical company focused on developing oral therapies to modulate protein levels for cancer and immune disorders. As of February 2025, it has a market cap of $868.32 million, with net sales of $18 million and a net loss of $56 million.

Overview: <BR>Nurix Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule therapies designed to modulate cellular protein levels for cancer and immune disorders, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 18 Million (Quarterly Results - Feb 2025) <BR>Most recent Net Profit: -56 Million (Quarterly Results - Feb 2025) <BR>Market-cap: USD 868.32 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.13 <BR>Return on Equity: -43.33% <BR>Price to Book: 1.81<BR><BR>Contact Details: <BR>Address: 1700 Owens St Ste 205, SAN FRANCISCO CA: 94158-0006 <BR>Tel: 1 415 6605320 <BR>Fax: 1 415 5254200 <BR>Website: https://www.nurixtx.com/

Should I buy, sell or hold Nurix Therapeutics, Inc.?

Who are in the management team of Nurix Therapeutics, Inc.?

As of March 2022, the management team of Nurix Therapeutics, Inc. includes Dr. David Lacey (Independent Non-Executive Chairman), Dr. Arthur Sands (President and CEO), and several Independent Directors: Dr. Leon Chen, Ms. Julia Gregory, Dr. Lori Kunkel, and Dr. Jeffrey Tong. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Nurix Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. David Lacey, who serves as the Independent Non-Executive Chairman of the Board.<BR>- Dr. Arthur Sands, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Leon Chen, who is an Independent Director.<BR>- Ms. Julia Gregory, who is also an Independent Director.<BR>- Dr. Lori Kunkel, another Independent Director.<BR>- Dr. Jeffrey Tong, who serves as an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Nurix Therapeutics, Inc. technically bullish or bearish?

As of August 26, 2025, Nurix Therapeutics, Inc. is in a bearish trend with strong indicators across multiple time frames, significantly underperforming the S&P 500 with year-to-date and one-year returns of -52.39% and -63.74%, respectively.

As of 26 August 2025, the technical trend for Nurix Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with strong indicators supporting this view. The MACD is bearish on both weekly and monthly time frames, and Bollinger Bands also indicate a bearish trend in both periods. Daily moving averages confirm a bearish outlook. The KST is bearish weekly and mildly bearish monthly, while the OBV shows a bearish trend across both time frames. According to Dow Theory, the stock is mildly bearish weekly and monthly.<BR><BR>In terms of performance, Nurix has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -52.39% versus the S&P 500's 12.22%, and a one-year return of -63.74% compared to the S&P 500's 17.14%.